ArticleCase reports in urology2025
A Rare Case of Primary Signet Ring Cell Carcinoma of the Urinary Bladder in a Young Woman.
Article in Case reports in urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary signet ring cell carcinoma of the urinary bladder (PSRCCB) is an exceedingly rare subtype of urinary bladder carcinoma, comprising 0.12%-0.6% of cases, with a poor prognosis. This case report details a distinctive case of a 32-year-old woman with PSRCCB, presenting without typical risk factors and posing diagnostic and therapeutic challenges. Initial symptoms included urinary tract infection and lower abdominal pain. Imaging and histological assessments identified a mucinous adenocarcinoma with signet ring cell components. The patient underwent curative open partial cystectomy, given her young age and localized tumor, avoiding lymphadenectomy and adjuvant chemotherapy due to complete tumor resection and absence of metastases. Postoperative follow-up showed no pathological findings, underscoring the importance of individualized treatment strategies in rare cancer cases. This case contributes to the limited data on PSRCCB and its management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.